BioCentury | Dec 21, 2018
Financial News

Inscripta adds $30M to series C to speed use of its gene editing tools

Inscripta Inc. (Boulder, Colo.) added an untranched $30 million to its series C round to accelerate development and adoption of its CRISPR gene-editing enzymes and tools. The company had raised $55.5 million in February from...
BioCentury | Dec 19, 2018
Financial News

Inscripta adds $30M to series C to speed use of its gene editing tools

Inscripta Inc. (Boulder, Colo.) added an untranched $30 million to its series C round to accelerate development and adoption of its CRISPR gene-editing enzymes and tools. The company had raised $55.5 million in February from...
BioCentury | Mar 2, 2018
Finance

Genome toolbox

The syndicate behind Inscripta Inc.’s $55.5 million series C round includes investors well-versed in genome reading and writing that are making a foray into genome editing. New investor Mérieux Développement and existing investor Paladin Capital...
BioCentury | Feb 28, 2018
Financial News

Inscripta raises $55.5M series C

Gene editing play Inscripta Inc. (Boulder, Colo.) raised $55.5 million in a series C round led by Mérieux Développement and Paladin Capital Group. Existing investors Venrock, Foresite Capital, MLS Capital and NanoDimension also participated. In...
BioCentury | Jan 13, 2017
Financial News

Ivantis completes venture financing

Ivantis raised $25 million in a series C round led by RA Capital Management. New investor Mérieux Développement and existing investors participated. Ivantis Inc. , Irvine, Calif. Alicia Parker Ivantis Inc....
BioCentury | Sep 12, 2016
Finance

Angelic patience

...early in 2018. Existing undisclosed angels led the tranched series E and were joined by Merieux Developpement...
BioCentury | Sep 12, 2016
Financial News

Proclara Biosciences completes venture financing

...Cambridge, Mass. Business: Neurology, Endocrine/Metabolic Date completed: 2016-09-07 Type: Venture financing Raised: $47 million Investors: Merieux Developpement...
BioCentury | Sep 7, 2016
Financial News

Proclara raises $47M

...raised $47 million in a series E round with existing investors, including undisclosed angels and Merieux Developpement...
BioCentury | May 19, 2016
Finance

Found in translation

Mark Zipkin, Staff Writer With almost $1 billion in new venture funds in the last year and a half aimed at academic research, Europe is showing signs of a dedicated effort among investors and universities...
BioCentury | Jan 25, 2016
Finance

Platform Twist

...D round is expected to be Twist's final private financing. Crossover backers Arch Overage Fund, Merieux Developpement...
Items per page:
1 - 10 of 28
BioCentury | Dec 21, 2018
Financial News

Inscripta adds $30M to series C to speed use of its gene editing tools

Inscripta Inc. (Boulder, Colo.) added an untranched $30 million to its series C round to accelerate development and adoption of its CRISPR gene-editing enzymes and tools. The company had raised $55.5 million in February from...
BioCentury | Dec 19, 2018
Financial News

Inscripta adds $30M to series C to speed use of its gene editing tools

Inscripta Inc. (Boulder, Colo.) added an untranched $30 million to its series C round to accelerate development and adoption of its CRISPR gene-editing enzymes and tools. The company had raised $55.5 million in February from...
BioCentury | Mar 2, 2018
Finance

Genome toolbox

The syndicate behind Inscripta Inc.’s $55.5 million series C round includes investors well-versed in genome reading and writing that are making a foray into genome editing. New investor Mérieux Développement and existing investor Paladin Capital...
BioCentury | Feb 28, 2018
Financial News

Inscripta raises $55.5M series C

Gene editing play Inscripta Inc. (Boulder, Colo.) raised $55.5 million in a series C round led by Mérieux Développement and Paladin Capital Group. Existing investors Venrock, Foresite Capital, MLS Capital and NanoDimension also participated. In...
BioCentury | Jan 13, 2017
Financial News

Ivantis completes venture financing

Ivantis raised $25 million in a series C round led by RA Capital Management. New investor Mérieux Développement and existing investors participated. Ivantis Inc. , Irvine, Calif. Alicia Parker Ivantis Inc....
BioCentury | Sep 12, 2016
Finance

Angelic patience

...early in 2018. Existing undisclosed angels led the tranched series E and were joined by Merieux Developpement...
BioCentury | Sep 12, 2016
Financial News

Proclara Biosciences completes venture financing

...Cambridge, Mass. Business: Neurology, Endocrine/Metabolic Date completed: 2016-09-07 Type: Venture financing Raised: $47 million Investors: Merieux Developpement...
BioCentury | Sep 7, 2016
Financial News

Proclara raises $47M

...raised $47 million in a series E round with existing investors, including undisclosed angels and Merieux Developpement...
BioCentury | May 19, 2016
Finance

Found in translation

Mark Zipkin, Staff Writer With almost $1 billion in new venture funds in the last year and a half aimed at academic research, Europe is showing signs of a dedicated effort among investors and universities...
BioCentury | Jan 25, 2016
Finance

Platform Twist

...D round is expected to be Twist's final private financing. Crossover backers Arch Overage Fund, Merieux Developpement...
Items per page:
1 - 10 of 28